Phase 4
Completed N=10
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
Source: ClinicalTrials.gov NCT03097068 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Oct 2022
Primary outcomePrimary: Vascular Endothelial Growth Factor Levels — 73.46 pg/ml
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vascular Endothelial Growth Factor Levels |
73.46 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of diabetes mellitus
- Best corrected visual acuity 20/32 - 20/320
- Diabetic macular edema involving the center of the macula
- Optical coherence tomography central subfield thickness of at least 250 microns
Exclusion Criteria
- History of anti-vascular endothelial growth factor treatment in the past 12 months
- Any diabetic macular edema treatment in the past 4 months
- Heart attack, stroke, transient ischemic attack or acute congestive heart failure within 4 months
Data sourced from ClinicalTrials.gov (NCT03097068). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.